SCHEMBL7806992

SCHEMBL7806992

O=C(Nc1ccccc1)Nc1ccc(NS(=O)(=O)c2cccc(-c3ccc(F)cc3)c2)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 5/20 0.58
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
LMNA P02545 3/20 0.53
MAPT P10636 3/20 0.53
NPSR1 Q6W5P4 3/20 0.53
MAPK1 P28482 2/20 0.53
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
IDH2 P48735 6/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
STING1 Q86WV6 1/20 0.51
KDM4E B2RXH2 1/20 0.49
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7805723 0.92 CNR1 (0.58) CNR1MEN1KMT2ALMNAMAPT
SCHEMBL7797518 0.88 CNR1 (0.56) CNR1MEN1KMT2ALMNAMAPT
SCHEMBL7798880 0.88 MAPT (0.55) CNR1MEN1KMT2ALMNAMAPT
SCHEMBL7805558 0.87 IDH2 (0.61) CNR1MEN1KMT2ALMNAMAPT
SCHEMBL7804129 0.86 PFKFB3 (0.60) CNR1MEN1KMT2ALMNAMAPT
SCHEMBL7811207 0.86 LMNA (0.55) CNR1MEN1KMT2ALMNAMAPT
SCHEMBL7805725 0.85 CNR1 (0.55) CNR1MEN1KMT2ALMNAMAPT
SCHEMBL7803343 0.85 MAPT (0.69) CNR1MEN1KMT2ALMNAMAPT
SCHEMBL7804642 0.83 KMT2A (0.70) MEN1KMT2ALMNAMAPTNPSR1
SCHEMBL7805075 0.82 IDH2 (0.54) CNR1MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B CNR1 174/4885MEN1 4730/4885KMT2A 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.